Dionisios Stoumbos

Accomplished Hematology Consultant with extensive clinical, research, and teaching experience in leading oncology and transplant centers. Expertise includes the management of hematologic malignancies, bone marrow transplantation, and advanced targeted therapies, including CAR-T cell treatments.

Actively engaged in international clinical trials and a key contributor to innovative treatment strategies that enhance patient outcomes. Recognized for clinical leadership, adept decision-making in complex cases, and fostering effective collaboration within multidisciplinary teams.

Recognized for strong academic and teaching contributions, including lecturing medical students and healthcare professionals, mentoring junior physicians, and presenting at national and international congresses. Trilingual (English, Greek, Romanian) with excellent communication, leadership, and interdisciplinary collaboration skills.

2003 to November 2006

Product Support (R&D) Scientist, January, Instrumentation Laboratory, Orangeburg, NY, USA.

November 2006 to May 2007

Quality Assurance Scientist, Instrumentation Laboratory, Orangeburg, NY, USA.

• Experience in the development process including discovery and optimization, of new products;
• Write/revise SOPs, QCMs, RMMs, Validation Protocols and Reports, CA/PA, Field Testing;
• Responsible for verifying, documenting, testing, and reporting customer complaints;
• Expert in troubleshooting and operation of diagnostic instrumentation such as liquid-handling robotics, micro-arrays, mass spectrometry, etc.;
• Coordinate with marketing, QC and R&D and provide product and project management in order to meet and exceed the customer expectations;
• Conduct stability and microbiology investigations for product performance improvement;
• Monitor and assure Quality Control of reagents, calibrators and controls;
• Familiar with FDA and ISO Regulations;
• In depth knowledge of the manufacturing process.

• European Hematology Association Member
• Hellenic Society of Hematology Member
• Medical Association of Piraeus (2007-present)
• Medical Doctor Licensure (2007-Current)
• American Red Cross Certified Instructor (CPR and/ or AED)
• Member of the Safety Committee during my employment in Instrumentation Laboratory.

• EUMELIA (54767414LEU2002)
  Sponsor: Hellenic Society of Hematology
  Role: Sub-Investigator (SI)
  Title: Phase II, multicenter, open-label, single-arm, prospective clinical trial evaluating the efficacy and safety of alternating bortezomib-based regimens combined with daratumumab, followed by daratumumab maintenance therapy in the frontline treatment of primary plasma cell leukemia.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• EAE116 (IsaVCd)
  Sponsor: Hellenic Society of Hematology
  Role: Sub-Investigator (SI)
  Title: Phase II study assessing isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone, followed by isatuximab + lenalidomide maintenance, in newly diagnosed multiple myeloma patients with severe renal impairment.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• EAE115 (IsaPomDex)
  Sponsor: Hellenic Society of Hematology
  Role: Sub-Investigator (SI)
  Title: Phase II study investigating isatuximab combined with pomalidomide and dexamethasone in multiple myeloma patients who have received one prior line of therapy containing lenalidomide and a proteasome inhibitor.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• BEaMM (217240)
  Sponsor: GSK & Syneos Health
  Role: Sub-Investigator (SI)
  Title: Multinational, non-interventional, real-world evidence study evaluating the effectiveness and safety of belantamab mafodotin (BLENREP) in patients with relapsed or refractory multiple myeloma across Europe.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• IONA-MM (OBS 16577)
  Sponsor: IQVIA & Sanofi
  Role: Sub-Investigator (SI)
  Title: Multinational, non-interventional, observational study assessing the real-world use, safety, and efficacy of isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM).
  Principal Investigator: Dr. Maria Kotsopoulou

• METER (H23-122)
  Sponsor: AbbVie
  Role: Sub-Investigator (SI)
  Title: Multicenter, real-world, retrospective study investigating treatment patterns, clinical outcomes, and healthcare resource utilization in patients diagnosed with multiple myeloma through medical record review.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• CORONIS (mm-eae-001)
  Sponsor: Hellenic Society of Hematology
  Role: Study Coordinator (SC) / Sub-Investigator (SI)
  Title: Non-interventional, prospective cohort study evaluating the effectiveness and safety of selinexor-based first-line regimens in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with anti-CD38–containing therapies in real-world Greek clinical practice.
  Principal Investigator: Dr. Maria Kotsopoulou
  
• BACTERAEMIA STUDY
  Sponsor: Hellenic Society of Hematology
  Role: Sub-Investigator (SI)
  Title: Multicenter, non-interventional, prospective study on the incidence, risk factors, and clinical outcomes of bacteremia caused by multidrug-resistant Gram-negative bacteria in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation.

2025 

Stoumbos D., Douna S., Antoniou A., Zikou K., Kapsokolis S., Xirokosta A., Dadakaridou M., Tsakiridou A., Kotsopoulou M.

"Real-World Use and Effectiveness of Venetoclax in Combination with Carfilzomib Plus Dexamethasone in t(11;14)-positive Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Study." 

IMS 2025 – Toronto, Canada. Poster Presentation.

2025 

Katodritou E., Kastritis E., Dalampira D., Kanellias N., Labropoulou V., Kyriakidis G., Douka V., Delimpasi S., Stoumbos D., et al.. 

"Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group." 

American Journal of Hematology. 

First published: June 3, 2025. https://doi.org/10.1002/ajh.27725

2024

Katodritou E., Kastritis E., Dalampira D., Stoumbos D., et al.. 

"Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group." 

Blood 144(Suppl 1):4673. November 2024. https://doi.org/10.1182/blood-2024-203776

2024

Verrou E., Papageorgiou S.G., Bouzani M., Stoumbos D., et al.. 

"Clinical Characteristics and Outcome of Early-Stage Diffuse Large B-Cell Lymphoma of the Female Genital Tract: A Retrospective Study of the Hellenic Cooperative Lymphoma Group." 

Hematological Oncology 42(5). August 2024. https://doi.org/10.1002/hon.3303

2017

Stoumbos D., Gkekas C., Asmanis E., Christaki E.E., Dadakaridou M., Lampropoulou P., Megalakaki A., Repousis P., Kotsopoulou M.. 

"Primary Bone Lymphoma: Real-World Experience of a Single Cancer Hospital – Results, Prognostic Factors, Treatment, and Long-Term Follow-Up of 12 Patients." 

Journal of Clinical Oncology (ASCO 2017). May 2017. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e19033

2017

Terpos E., Katodritou E., Kotsopoulou M., Ntanasis-Stathopoulos I., Lampropoulou P., Papadaki S., Papathanasiou M., Stoumbos D., et al.. 

"Real-World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Study of the Greek Myeloma Study Group." 

EHA Learning Center. Abstract 181025, May 2017. https://learningcenter.ehaweb.org/eha/2017/22nd/181025

2016

Kotsopoulou M., Stoumbos D., Perlorentzou S., Kouloukakou E., Ziras N., Papaemmanouil V.. 

"The Epidemiological Profile of Hospital-Acquired Infections Due to Multidrug-Resistant Pathogens in Patients with Hematologic Malignancies and Solid Neoplasms: Real-World Experience of a Single Cancer Hospital." 

Journal of Clinical Oncology (ASCO 2016). May 2016. http://ascopubs.org/action/doSearch?target=default&ContribAuthorStored=Stoumbos,%20Dionisios

2015

Stoumbos D., Patsias I., Asmanis E., Christaki E.E., Katsiva V., Tasidou A., Kyrtsonis M.C., Repousis P., Kotsopoulou M.. 

"Bing-Neel Syndrome at Diagnosis of Waldenström: An Extremely Rare Case Report." 

Blood 126:5065. http://www.bloodjournal.org/content/126/23/5065?sso-checked=true

2015

Tsakiridou A., Lampropoulou P., Anastasiadis A., Papageorgiou G., Stoumbos D., Patsias I., Gekas C., Kotsopoulou M., Repousis P., Megalakaki A.. "Clinical Prognostic Factors of Long-Term Survival in Multiple Myeloma." 

EHA 2015 – Vienna, Austria. http://learningcenter.ehaweb.org/eha/2015/20th/103020/anastasia.tsakiridou.clinical.prognostic.factors.of.long.term.survival.html

2015

Stoumbos D., Asmanis E., Christaki E.E., Gkekas C., Papageorgiou G., Lampropoulou P., Patsias I., Megalakaki A., Tsakiridou A., Repousis P., Kotsopoulou M.. 

"High Serum Lactate Dehydrogenase Level Used as a Prognostic Factor in Multiple Myeloma." 

Clinical Lymphoma, Myeloma & Leukemia (IMW 2015, Rome). Vol. 15, Suppl 3, pp. e126–e127. 

http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(15)00752-1/pdf

2015

Stoumbos D..

"Serum Lactate Dehydrogenase Does Not Predict Overall Survival in Myeloma." 

Haelio HemOncToday – Meeting Coverage. October 23, 2015. 

http://www.healio.com/hematology-oncology/hematologic-malignancies/news/online/%7B206264d3-165c-4582-ac8a-e4a3ac4c6bb8%7D/serum-lactate-dehydrogenase-does-not-predict-os-in-myeloma

2025

Non-Promotional Scientific Meeting – “New Horizons in the Therapeutic Management of Patients with CLL & MCL: From Latest Evidence to Daily Clinical Practice”
Talk: “Management Data of Patients with Relapsed/Refractory CLL”
Location: Athens, Greece | Date: September 5, 2025

2025

Scientific Event – “Supporting the Hematologic Patient in the Era of Innovative Therapies”
Talk: “Iron Overload in Acquired Sideroblastic Anemias and Myelodysplastic Syndromes: The Role of Chelation and Luspatercept”
Location: Thessaloniki, Greece | Date: June 27–29, 2025

2024

Scientific Symposium – “Optimizing the Present, Opening New Horizons III”
Talk: “Novel Therapeutic Approaches in Chronic Lymphocytic Leukemia”
Chairperson: I. Papakonstantinou
Location: Greece | Date: September 13–14, 2024

2023

Joint Scientific Meeting – Hellenic Society of Hematology (Departments of Plasma Cell Dyscrasias, Lymphoproliferative Disorders, Blood Donation Academy, Macedonia–Thrace Division)
Talk: “Relapsed/Refractory Myeloma”
Location: Megaron Athens Concert Hall, Greece | Date: May 5–6, 2023

2023

8th Multiple Myeloma Forum
Talk: “Management of Relapsed/Refractory Patients”
Location: Arachova, Greece | Date: April 1–2, 2023

2023 

Educational Workshop on Multiple Myeloma – Integris Pharma
Role: Invited Speaker
Location: Athens, Greece | Date: March 11–12, 2023

2022

Scientific Symposium – “Optimizing the Present, Opening New Horizons”

Talk: “Novel Therapeutic Approaches in Chronic Lymphocytic Leukemia” 

Location: Byzantino Hotel, Patras, Greece | Date: September 23–24, 2022

• Member of the 5S Audit Committee during my employment in Instrumentation Laboratory;
• Member of the Environmental Audit Team during my employment in Instrumentation Laboratory;
• Annual audits by FDA and ISO during my employment at IL where I was interviewed for my projects, corrective and preventive actions to ensure that correct procedures were followed and validations were developed in accordance with the regulations

• More than 6 years of medical practice at renowned hospitals/clinics, good diagnosing abilities developed through studies and practice;
• Able to interact efficiently with patients from all age groups;
• Familiarity with the laws about usage of various medicinal drugs and their prescribing procedures;
• Frequent lecturer to student groups on variety of medical topics. Highly skilled in evaluating, training, and instructing;
• Proficiency in handling computerized tools;
• Expert in State-of-the-art Diagnostic analyzers and instrumentation;
• Fully competent to plan and conduct scientific assignments and provide product support in clinical research and technical development areas;
• Experienced in handling changing work load and manage multiple tasks.

• ICH GOOD CLINICAL PRACTICE E6 (R2) with a score of 100% on 12/02/2025
• Organized, efficient, responsible with excellent communication skills.
• Good Medical Practice and good moral character
• IERF Certification
• Certification for operation and troubleshooting of DPC Immunology and Serology analyzers.